Suppression of tumor angiogenesis through the inhibition of integrin function and signaling in endothelial cells: Which side to target?

Endothelium: Journal of Endothelial Cell Research

Volumn 9, Issue 3, 2002, Pages 151-160

  Rüegg, Curzio ^a   Dormond, O ^a   Foletti, A ^a  

^a SWISS INST FOR EXP CANCER RESEARCH   (Switzerland)

Author keywords

Angiogenesis; Cancer; Integrins; NSAIDs; Therapy

Indexed keywords

ALPHA INTERFERON; ALPHA V BETA3 INTEGRIN; ALPHA V BETA3 INTEGRIN ANTAGONIST; ALPHA V BETA5 INTEGRIN ANTAGONIST; ANGIOGENESIS INHIBITOR; ANGIOSTATIN; ANTIBODY; ANTINEOPLASTIC AGENT; CILENGITIDE; CYCLOOXYGENASE 2; ENDOSTATIN; ENZYME INHIBITOR; FOCAL ADHESION KINASE; GAMMA INTERFERON; INTEGRIN; INTERLEUKIN 12; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MONOCLONAL ANTIBODY LM 609; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PEPTIDE; PRINOMASTAT; PROTEIN TYROSINE KINASE INHIBITOR; SEMAXANIB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN ANTIBODY; VASCULOTROPIN RECEPTOR 2; VATALANIB;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BLOOD VESSEL; CANCER; CANCER INHIBITION; CANCER MODEL; CARCINOGENESIS; CELL ADHESION; CELL MIGRATION; CELL SURVIVAL; CLINICAL TRIAL; CYTOPLASM; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; ENDOTHELIUM CELL; EVIDENCE BASED MEDICINE; HUMAN; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; CELL ADHESION MOLECULES; CYCLOOXYGENASE 2; DRUG DELIVERY SYSTEMS; ENDOTHELIUM, VASCULAR; HUMANS; INTEGRIN ALPHAVBETA3; INTEGRINS; INTERFERON TYPE II; ISOENZYMES; MEMBRANE PROTEINS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; RHO GTP-BINDING PROTEINS; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036039315     PISSN: 10623329     EISSN: None     Source Type: Journal    
DOI: 10.1080/10623320213635     Document Type: Review

References (134)

1. Aspirin and risk for gastric cancer: A population-based case-control study in Sweden
2. Matrix attachment regulates Fas-induced apoptosis in endothelial cells: A role for c-Flip and implications for anoikis
3. Isolation of putative progenitor endothelial cells for angiogenesis
4. The integrin-linked kinase (ILK) suppresses anoikis
5. Extensive vasculogenesis, angiogenesis, and organogenesis precede lethality in mice lacking all alpha v integrins
6. Alpha(v)beta3 and alpha(v)beta5 integrin expression in glioma periphery
7. Is angiogenesis inhibition the Holy Grail of cancer therapy?
8. Identification of a novel class of small-molecule antiangiogenic agents through the screening of combinatorial libraries which function by inhibiting the binding and localization of proteinase MMP2 to integrin alpha(V)beta(3)
9. Requirement of vascular integrin alpha v beta 3 for angiogenesis
10. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
11. Antiintegrin alpha v beta 3 blocks human breast cancer growth and angiogenesis in human skin
12. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin alpha v beta 3
13. Focal adhesion assembly
14. A mechanism for modulation of cellular responses to VEGF: Activation of the integrins
15. The regulation of anoikis: MEKK-1 activation requires cleavage by caspases
16. Angiogenesis in cancer and other diseases
17. An endotoxin-induced serum factor that causes necrosis of tumors
18. Human endothelial cells synthesize and express an Arg-Gly-Asp-directed adhesion receptor involved in attachment to fibrinogen and von Willebrand factor
19. Integrin-mediated death: An explanation of the integrin-knockout phenotype?
20. International Union of Pharmacology classification of prostanoid receptors: Properties, distribution, and structure of the receptors and their subtypes
21. Endothelial cell integrin alpha5beta1 expression is modulated by cytokines and during migration in vitro
22. Recent advances in research on multistage tumorigenesis
23. cAMP-dependent protein kinase inhibits the mitogenic action of vascular endothelial growth factor and fibroblast growth factor in capillary endothelial cells by blocking Raf activation
24. Cellular survival: A play in three Akts
25. Cell anchorage regulates apoptosis through the retinoblastoma tumor suppressor/E2F pathway
26. N-Methylated cyclic RGD peptides as highly active and selective alpha(V)beta(3) integrin antagonists
27. Circulating endothelial cells in acute coronary syndromes
28. NSAIDs inhibit alpha Vbeta3 integrin-mediated and Cdc42/Rac-dependent endothelial-cell spreading, migration and angiogenesis
29. TNF and IFNgamma induced G1/S block in human endothelial cells is associated with expression of p16INK4a
30. Inhibition of tumor angiogenesis by nonsteroidal anti-inflammatory drugs: Emerging mechanisms and therapeutic perspectives
31. A conserved sequence motif in the integrin beta3 cytoplasmic domain is required for its specific interaction with beta3-endonexin
32. Role of alpha V integrins during angiogenesis
33. Integrin alphavbeta3 requirement for sustained mitogen-activated protein kinase activity during angiogenesis
34. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling
35. Rho family proteins in cell adhesion and cell migration
36. Tumor angiogenesis: Therapeutical implications
37. Angiogenesis in cancer, vascular, rheumatoid and other disease
38. Induction of angiogenesis during the transition for hyperplasia to neoplasia
39. Definition of two angiogenic pathways by distinct alpha v integrins
40. Disruption of epithelial cell-matrix interactions induces apoptosis
41. Integrins and anoikis
42. A role for Jun-N-terminal kinase in anoikis; Suppression by bcl-2 and crmA
43. Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function
44. Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo
45. Transduction - Integrin signaling
46. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
47. Potentiation of the antitumor effect of ionizing radiation by brief concomitant exposures to angiostatin
48. Angiogenesis: Potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation
49. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2
50. Targeted antiangiogenic therapy for cancer using Vitaxin: A humanized monoclonal antibody to the integrin alphavbeta3
51. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization
52. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
53. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
54. Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression
55. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature
56. Cell adhesion: Old and new questions
57. Reduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
58. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: Insight into mechanisms and implications for cancer growth and ulcer healing
59. Transplantation of ex vivo expanded endothelial progenitor cells for therapeutic neovascularization
60. Tumor angiogenesis: Past, present and the near future
61. Establishing a link between oncogenes and tumor angiogenesis
62. Matrix adhesion and Ras transformation both activate a phosphoinositide 3-OH kinase and protein kinase B/Akt cellular survival pathway
63. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin
64. Regulation of integrin alpha vbeta 3-mediated endothelial cell migration and angiogenesis by integrin alpha5beta1 and protein kinase A
65. Src family kinases are required for integrin but not PDGFR signal transduction
66. Integrins and inside-out signal transduction: Converging signals from PKC and PIP3
67. Single subunit chimeric integrins as mimics and inhibitors of endogenous integrin functions in receptor localization, cell spreading and migration, and matrix assembly
68. Integrin beta 1- and beta 3-mediated endothelial cell migration is triggered through distinct signaling mechanisms
69. Alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B-dependent pathway
70. Clinical applications of TNF-alpha in cancer
71. High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma
72. Identification of a functionally important sequence in the cytoplasmic tail of integrin beta 3 by using cell-permeable peptide analogs
73. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases
74. Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels
75. Disruption of integrin function and induction of tyrosine phosphorylation by the autonomously expressed beta 1 integrin cytoplasmic domain
76. Therapeutic synergy of TNP-470 and ionizing radiation: Effects on tumor growth, vessel morphology, and angiogenesis in human glioblastoma multiforme xenografts
77. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth
78. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
79. Preferential susceptibility of brain tumors to the antiangiogenic effects of an alpha(v) integrin antagonist
80. Tumor vascular targeting using a tumor-tissue endothelium-specific monoclonal antibody as an effective strategy for cancer chemotherapy
81. Resting and activated endothelial cells are increased in the peripheral blood of cancer patients
82. Immunohistochemical analysis of integrin alpha vbeta3 expression on tumor-associated vessels of human carcinomas
83. The extracellular matrix as a cell survival factor
84. Sensing the environment: A historical perspective on integrin signal transduction
85. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin
86. Transplanted cord blood-derived endothelial precursor cells augment postnatal neovascularization
87. Targeted delivery of tissue factor to the ED-B domain of fibronectin, a marker of angiogenesis, mediates the infarction of solid tumors in mice
88. Disruption of integrin-dependent adhesion and survival of endothelial cells by recombinant adenovirus expressing isolated beta integrin cytoplasmic domains
89. Angiostatin induces and sustains dormancy of human primary tumors in mice
90. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
91. Alpha v integrins as receptors for tumor targeting by circulating ligands
92. Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke
93. A pilot trial of Vitaxin, a humanized anti-vitronectin receptor (anti alpha v beta 3) antibody in patients with metastatic cancer
94. Inhibition of anchorage-dependent cell spreading triggers apoptosis in cultured human endothelial cells
95. Enhanced pathological angiogenesis in mice lacking beta3 integrin or beta3 and beta5 integrins
96. Mechanisms of angiogenesis
97. Evidence for the involvement of endothelial cell integrin alpha-v-beta-3 in the disruption of the tumor vasculature induced by TNF and IFN-gamma
98. NF-kappaB mediates alphavbeta3 integrin-induced endothelial cell survival
99. Potentiation of platinum antitumor effects in human lung tumor xenografts by the angiogenesis inhibitor squalamine: Effects on tumor neovascularization
100. Vascular targeting as a strategy for cancer therapy
101. Integrins: Emerging paradigms of signal transduction
102. Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: Single agent and combination chemotherapy studies
103. Evidence for circulating bone marrow-derived endothelial cells
104. The role of cyclooxygenase inhibition in the antineoplastic effects of nonsteroidal antiinflammatory drugs (NSAIDs)
105. Required role of focal adhesion kinase (FAK) for integrin-stimulated cell migration
106. Detection of tumor angiogenesis in vivo by alpha V beta 3-targeted magnetic resonance imaging
107. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis
108. Role of alphavbeta3 integrin in the activation of vascular endothelial growth factor receptor-2
109. Circulating activated endothelial cells in sickle cell anemia
110. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics
111. Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis
112. Loss of p53 compensates for alpha v-integrin function in retinal neovascularization
113. Apoptosis of adherent cells by recruitment of caspase-8 to unligated integrins
114. P53, vessel count, and vascular endothelial growth factor expression in human colon cancer
115. Reduced blood vessel formation and tumor growth in alpha5-integrin-negative teratocarcinomas and embryoid bodies
116. Aspirin use and reduced risk of fatal colon cancer
117. The integrin linked kinase (ILK) induces an invasive phenotype via AP-1 transcription factor-dependent upregulation of matrix metalloproteinase 9 (MMP-9)
118. Cyclooxygenase regulates angiogenesis induced by colon cancer cells
119. Cyclooxygenases 1 and 2
120. Tumor angiogenesis and the role of vascular cell integrin alphavbeta3
121. Tumor angiogenesis and metastasis - Correlation in invasive breast carcinoma
122. A growing role for Rho family GTPases as intermediaries in growth factor- and adhesion-dependent cell cycle progression
123. The role of cyclooxygenases in inflammation, cancer, and development
124. Host cyclooxygenase-2 modulates carcinoma growth
125. Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis
126. Crystal structure of the extracellular segment of integrin alpha Vbeta3
127. Crystal structure of the extracellular segment of integrin alpha Vbeta3 in complex with an Arg-Gly-Asp ligand
128. Vascular-specific growth factors and blood vessel formation
129. Pulse treatment of human vascular endothelial cells with high doses of tumor necrosis factor and interferon-gamma results in simultaneous synergistic and reversible effects on proliferation and morphology
130. Integrin-linked kinase (ILK): A "hot" therapeutic target
131. Synergy between angiostatin and endostatin: Inhibition of ovarian cancer growth
132. Angiogenesis and tumor metastasis
133. The alpha 5 beta 1 integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression